The Precision Cancer Consortium (PCC) announced its formation as a new collaboration of pharmaceutical companies with a shared vision of enabling access to comprehensive testing for all cancer patients globally.
Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
Silicon Valley medical equipment startup Visby Medical received Emergency Use Authorization by the U.S. Food and Drug Administration for a portable PCR Covid-19 test kit, the first company to do so, according to the FDA.
U.S. manufacturers are sharply increasing production of cheap, fast – but less accurate – Covid-19 tests, aiming for 100 million per month by year-end 2020 that will enable schools and workplaces to significantly expand testing.
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic DeviceAntibody Drug Conjugates (ADC), Business, Clinical Data, Clinical Trials, Companion Diagnostics, Diagnostic Tools, HER2 Mutations, Next-Generation Sequencing (NGS), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Partnerships, R&D
Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).
Michigan-based ENDRA Life Sciences is developing Thermo-Acoustic Enhanced UltraSound (TAEUS), which could become a revolutionary diagnostics tool for doctors.
The FDA approved Gadavist for use in cardiac magnetic resonance imaging to assess myocardial perfusion and late gadolinium enhancement in adults with known or suspected CAD.
Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug.
A team led by Kaiser Permanente researchers has developed and validated a practical tool for identifying diabetes patients who are at the highest risk for being admitted to an emergency department or hospital due to severe hypoglycemia, or very low blood sugar.